sooner rather than later. $4m cash at end of Dec 2023. $1.4 M R&D spend for that Dec quarter which was before recruitment for next stage including Korea started, trial costs are only going one way and that’s up.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-14
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.002(2.86%) |
Mkt cap ! $19.55M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.2¢ | 7.0¢ | $5.99K | 84.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 819 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 8120 | 1 |
View Market Depth
| Last trade - 15.43pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
0.002 ( 1.41 %) |
||||
| Open | High | Low | Volume | ||
| 7.2¢ | 7.2¢ | 7.2¢ | 7895 | ||
| Last updated 13.20pm 06/06/2024 ? | |||||
| ATX (ASX) Chart |